LRRK2 at the Crossroad between Autophagy and Microtubule Trafficking: Insights into Parkinsons Disease

Neuroscientist

Volumn 23, Issue 1, 2017, Pages 16-26

  Esteves, A Raquel ^a,b   Cardoso, Sandra M ^a,b,c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

endosomal autophagic pathway; LRRK2; lysosomal homeostasis; microtubule dynamics; mitochondrial function; Parkinson's disease

Indexed keywords

ACTIN; ALPHA TUBULIN; BETA TUBULIN; LEUCINE RICH REPEAT KINASE 2; RAB7 PROTEIN; TAU PROTEIN;

ACETYLATION; ALZHEIMER DISEASE; AUTOPHAGY; CALCIUM TRANSPORT; CELL FUNCTION; CYTOSKELETON; DEGENERATIVE DISEASE; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HOMEOSTASIS; HUMAN; MICROTUBULE; MICROTUBULE ASSEMBLY; MITOCHONDRION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; SHY DRAGER SYNDROME;

EID: 85011423442     PISSN: 10738584     EISSN: 10894098     Source Type: Journal    
DOI: 10.1177/1073858415616558     Document Type: Review

References (68)

1. Alegre-Abarrategui J, Christian H, Lufino MM, Mutihac R, Venda LL, Ansorge O, and others. 2009. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet 18: 4022-34.
2. Angeles DC, Gan BH, Onstead L, Zhao Y, Lim KL, Dachsel J, and others. 2011. Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death. Hum Mutat 32: 1390-7.
3. Anglade P, Vyas S, Javoy-Agid F, Herrero MT, Michel PP, Marquez J, and others. 1997. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 12: 25-31.
4. Arduino DM, Esteves AR, Cortes L, Silva DF, Patel B, Grazina M, and others. 2012. Mitochondrial metabolism in Parkinson's disease impairs quality control autophagy by hampering microtubule-dependent traffic. Hum Mol Genet 21: 4680-702.
5. Bailey RM, Covy JP, Melrose HL, Rousseau L, Watkinson R, Knight J, and others. 2013. LRRK2 phosphorylates novel tau epitopes and promotes tauopathy. Acta Neuropathol 126: 809-27.
6. Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, and others. 2006. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 60: 557-69.
7. Biskup S, Moore DJ, Rea A, Lorenz-Deperieux B, Coombes CE, Dawson VL, and others. 2007. Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMC Neurosci 8: 102.
8. Bravo-San Pedro JM, Niso-Santano M, Gomez-Sanchez R, Pizarro-Estrella E, Aiastui-Pujana A, Gorostidi A, and others. 2013. The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway. Cell Mol Life Sci 70: 121-36.
9. Caesar M, Zach S, Carlson CB, Brockmann K, Gasser T, Gillardon F,. 2013. Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration. Neurobiol Dis 54: 280-8.
10. Cardoso SM,. 2011. The mitochondrial cascade hypothesis for Parkinson's disease. Curr Pharm Des 17: 3390-7.
11. Chen-Plotkin AS, Yuan W, Anderson C, McCarty Wood E, Hurtig HI, Clark CM, and others. 2008. Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations. Neurology 70: 521-7.
12. Cherra SJ 3rd, Steer E, Gusdon AM, Kiselyov K, Chu CT,. 2013. Mutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neurons. Am J Pathol 182: 474-84.
13. Cooper O, Seo H, Andrabi S, Guardia-Laguarta C, Graziotto J, Sundberg M, and others. 2012. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med 4: 141ra190.
14. Dodson MW, Zhang T, Jiang C, Chen S, Guo M,. 2012. Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum Mol Genet 21: 1350-63.
15. Esteves AR, G-Fernandes M, Santos D, Januário C, Cardoso SM,. 2015. The upshot of LRRK2 inhibition to Parkinson's disease paradigm. Mol Neurobiol 52: 1804-20.
16. Esteves AR, Gozes I, Cardoso SM,. 2014a. The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson's disease. Biochim Biophys Acta 1842: 7-21.
17. Esteves AR, Swerdlow RH, Cardoso SM,. 2014b. LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis. Exp Neurol 261: 206-16.
18. Ferree A, Guillily M, Li H, Smith K, Takashima A, Squillace R, and others. 2012. Regulation of physiologic actions of LRRK2: focus on autophagy. Neurodegener Dis 10: 238-41.
19. Gillardon F,. 2009. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-β isoforms and modulates microtubule stability-a point of convergence in parkinsonian neurodegeneration? J Neurochem 110: 1514-22.
20. Godena VK, Brookes-Hocking N, Moller A, Shaw G, Oswald M, Sancho RM, and others. 2014. Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. Nat Commun 5: 5245.
21. Gomez-Suaga P, Luzon-Toro B, Churamani D, Zhang L, Bloor-Young D, Patel S, and others. 2012. Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum Mol Genet 21: 511-25.
22. Gomez-Suaga P, Rivero-Rios P, Fdez E, Blanca Ramirez M, Ferrer I, Aiastui A, and others. 2014. LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity. Hum Mol Genet 23: 6779-96.
23. Greggio E, Cookson MR,. 2009. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 1 (1).
24. Greggio E, Taymans JM, Zhen EY, Ryder J, Vancraenenbroeck R, Beilina A, and others. 2009. The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem Biophys Res Commun 389: 449-54.
25. Guerreiro PS, Gerhardt E, Lopes da, Fonseca T, Bähr M, Outeiro TF, Eckermann K,. 2015. LRRK2 promotes tau accumulation, aggregation and release. Mol Neurobiol. Epub 27. doi: 10.1007/s12035-015-9209-z.
26. Hatano T, Kubo S, Imai S, Maeda M, Ishikawa K, Mizuno Y, and others. 2007. Leucine-rich repeat kinase 2 associates with lipid rafts. Hum Mol Genet 16: 678-90.
27. Heo HY, Kim KS, Seol W,. 2010. Coordinate regulation of neurite outgrowth by LRRK2 and its interactor, Rab5. Exp Neurobiol 19: 97-105.
28. Hernandez D, Paisan Ruiz C, Crawley A, Malkani R, Werner J, Gwinn-Hardy K, and others. 2005. The dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. Neurosci Lett 389: 137-9.
29. Higashi S, Biskup S, West AB, Trinkaus D, Dawson VL, Faull RL, and others. 2007. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res 1155: 208-19.
30. Higashi S, Moore DJ, Yamamoto R, Minegishi M, Sato K, Togo T, and others. 2009. Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in Lewy body disease. J Neuropathol Exp Neurol 68: 994-1005.
31. Hyttinen JM, Niittykoski M, Salminen A, Kaarniranta K,. 2013. Maturation of autophagosomes and endosomes: a key role for Rab7. Biochim Biophys Acta 1833: 503-10.
32. Kawakami F, Shimada N, Ohta E, Kagiya G, Kawashima R, Maekawa T, and others. 2014. Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3β. FEBS J 281: 3-13.
33. Kawakami F, Yabata T, Ohta E, Maekawa T, Shimada N, Suzuki M, and others. 2012. LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS One 7: e30834.
34. Kett LR, Boassa D, Ho CC, Rideout HJ, Hu J, Terada M, and others. 2012. LRRK2 Parkinson disease mutations enhance its microtubule association. Hum Mol Genet 21: 890-9.
35. Law BM, Spain VA, Leinster VH, Chia R, Beilina A, Cho HJ, and others. 2014. A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation. J Biol Chem 289: 895-908.
36. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A,. 2006. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52: 587-93.
37. MacLeod DA, Rhinn H, Kuwahara T, Zolin A, Di Paolo G, McCabe BD, and others. 2013. RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron 77: 425-39.
38. Manzoni C, Mamais A, Dihanich S, Abeti R, Soutar MP, Plun-Favreau H, and others. 2013a. Inhibition of LRRK2 kinase activity stimulates macroautophagy. Biochim Biophys Acta 1833: 2900-10.
39. Manzoni C, Mamais A, Dihanich S, McGoldrick P, Devine MJ, Zerle J, and others. 2013b. Pathogenic Parkinson's disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation. Biochem Biophys Res Commun 441: 862-6.
40. Melrose HL, Dachsel JC, Behrouz B, Lincoln SJ, Yue M, Hinkle KM, and others. 2010. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis 40: 503-17.
41. Moore DJ,. 2008. The biology and pathobiology of LRRK2: implications for Parkinson's disease. Parkinsonism Relat Disord 14 (Suppl 2): S92-8.
42. Mortiboys H, Johansen KK, Aasly JO, Bandmann O,. 2010. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 75: 2017-20.
43. Niu J, Yu M, Wang C, Xu Z,. 2012. Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein. J Neurochem 122: 650-8.
44. Orenstein SJ, Kuo SH, Tasset I, Arias E, Koga H, Fernandez-Carasa I, and others. 2013. Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci 16: 394-406.
45. Papkovskaia TD, Chau KY, Inesta-Vaquera F, Papkovsky DB, Healy DG, Nishio K, and others. 2012. G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization. Hum Mol Genet 21: 4201-13.
46. Parisiadou L, Xie C, Cho HJ, Lin X, Gu XL, Long CX, and others. 2009. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci 29: 13971-80.
47. Ramonet D, Daher JP, Lin BM, Stafa K, Kim J, Banerjee R, and others. 2011. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 6: e18568.
48. Rudenko IN, Chia R, Cookson MR,. 2012. Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? BMC Med 10: 20.
49. Saez-Atienzar S, Bonet-Ponce L, Blesa JR, Romero FJ, Murphy MP, Jordan J, and others. 2014. The LRRK2 inhibitor GSK2578215A induces protective autophagy in SH-SY5Y cells: involvement of Drp-1-mediated mitochondrial fission and mitochondrial-derived ROS signaling. Cell Death Dis 5: e1368.
50. Saha S, Ash PE, Gowda V, Liu L, Shirihai O, Wolozin B,. 2015. Mutations in LRRK2 potentiate age-related impairment of autophagic flux. Mol Neurodegener 10: 26.
51. Saha S, Guillily MD, Ferree A, Lanceta J, Chan D, Ghosh J, and others. 2009. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci 29: 9210-8.
52. Sanchez-Danes A, Richaud-Patin Y, Carballo-Carbajal I, Jimenez-Delgado S, Caig C, Mora S, and others. 2012. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol Med 4: 380-95.
53. Sanders LH, Laganiere J, Cooper O, Mak SK, Vu BJ, Huang YA, and others. 2014. LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction. Neurobiol Dis 62: 381-6.
54. Santos-Reboucas CB, Abdalla CB, Martins PA, Baldi FJ, Santos JM, Motta LB, and others. 2009. LRRK2 p.G2019S mutation is not common among Alzheimer's disease patients in Brazil. Dis Markers 27: 13-6.
55. Schapansky J, Nardozzi JD, Felizia F, LaVoie MJ,. 2014. Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy. Hum Mol Genet 23: 4201-14.
56. Stafa K, Tsika E, Moser R, Musso A, Glauser L, Jones A, and others. 2014. Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily. Hum Mol Genet 23: 2055-77.
57. Su YC, Qi X,. 2013. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation. Hum Mol Genet 22: 4545-61.
58. Tan EK, Lee J, Chen CP, Wong MC, Zhao Y,. 2009. Case control analysis of LRRK2 Gly2385Arg in Alzheimer's disease. Neurobiol Aging 30: 501-2.
59. Tong Y, Giaime E, Yamaguchi H, Ichimura T, Liu Y, Si H, and others. 2012. Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol Neurodegener 7: 2.
60. Tong Y, Yamaguchi H, Giaime E, Boyle S, Kopan R, Kelleher RJ 3rd, and others. 2010. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A 107: 9879-84.
61. Wang X, Yan MH, Fujioka H, Liu J, Wilson-Delfosse A, Chen SG, and others. 2012. LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet 21: 1931-44.
62. Waschbusch D, Michels H, Strassheim S, Ossendorf E, Kessler D, Gloeckner CJ, and others. 2014. LRRK2 transport is regulated by its novel interacting partner Rab32. PLoS One 9: e111632.
63. Wong E, Cuervo AM,. 2010. Autophagy gone awry in neurodegenerative diseases. Nat Neurosci 13: 805-11.
64. Xiong Y, Coombes CE, Kilaru A, Li X, Gitler AD, Bowers WJ, and others. 2010. GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet 6: e1000902.
65. Yakhine-Diop SM, Bravo-San Pedro JM, Gomez-Sanchez R, Pizarro-Estrella E, Rodriguez-Arribas M, Climent V, and others. 2014. G2019S LRRK2 mutant fibroblasts from Parkinson's disease patients show increased sensitivity to neurotoxin 1-methyl-4-phenylpyridinium dependent of autophagy. Toxicology 324: 1-9.
66. Yang S, Xia C, Li S, Du L, Zhang L, Hu Y,. 2014. Mitochondrial dysfunction driven by the LRRK2-mediated pathway is associated with loss of Purkinje cells and motor coordination deficits in diabetic rat model. Cell Death Dis 5: e1217.
67. Zabetian CP, Lauricella CJ, Tsuang DW, Leverenz JB, Schellenberg GD, Payami H,. 2006. Analysis of the LRRK2 G2019S mutation in Alzheimer disease. Arch Neurol 63: 156-7.
68. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, and others. 2004. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44: 601-7.